VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Conditions
Head and Neck Carcinoma · Adenoid Cystic Carcinoma · Lung Cancer · Non-Small Cell Lung Cancer · Pancreatic Cancer · Mesothelioma · Esophageal Cancer · Any Solid Tumors Progressed After a Prior Immunotherapy · Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma HNSCC · Salivary Gland Carcinomas · Head and Neck Cancers - Salivary Gland · Head and Neck Cancers - Nasopharyngeal · Head and Neck Cancers - Throat · Small Cell Lung Cancer ( SCLC ) · Lung Cancer (Locally Advanced or Metastatic) · Head and Neck Cancers - Tonsils · Head and Neck Cancers Hypopharynx · Head and Neck Cancers Larynx · Head and Neck Cancers Lip · Head and Neck Cancers Nasopharynx · Head and Neck Cancers Oral Cavity · Head and Neck Cancers · Head and Neck Cancers Oropharynx · Head and Neck Cancers Trachea
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Providence Medical Foundation (site 209), Santa Rosa, California, United States
Contact: Principal Investigator (Ian C Anderson, MD)Hartford Hospital (site 210), Hartford, Connecticut, United States
Contact: Principal Investigator (Jaykumar Thumar, MD)The George Washington University Cancer Center (site 212), Washington D.C., District of Columbia, United States
Contact: Principal Investigator (Sonal Paul, MD)Holy Cross Hospital (site 213), Fort Lauderdale, Florida, United States
Contact: Principal Investigator (Georges Azzi, MD)Memorial Cancer Institute at Memorial Healthcare Systems (site 132), Pembroke Pines, Florida, United States
Contact: Principal Investigator (Luis E Raez, MD)Englewood Hospital and Medical Center (site 202), Englewood, New Jersey, United States
Contact: Principal Investigator (Minaxi Jhawer, MD)Summit Medical Group (site 205), Florham Park, New Jersey, United States
Contact: Principal Investigator (David Gallinson, DO)Atlantic Health System, Morristown Medical Center (site 124), Morristown, New Jersey, United States
Contact: Study coordinator (Tracey Hilden, RN, BSN, OCN) · Tracey.Hilden@atlantichealth.org · 973-971-7889Contact: Principal Investigator (Angela Alistar, MD)Presbyterian Kaseman Hospital (site 208), Albuquerque, New Mexico, United States
Contact: Principal Investigator (Ethan Binder, MD)Weill Cornell Medicine, Cornell University (site 126), New York, New York, United States
Contact: Principal Investigator (Barbara Ma, M.D., M.S.)Taylor Cancer Research Center (site 204), Maumee, Ohio, United States
Contact: Principal Investigator (John J Nemunaitis, MD)Cancer Care Associates of York (site 206), York, Pennsylvania, United States
Contact: Principal Investigator (Chanh Huynh, MD)The University of Texas MD Anderson Cancer Center (site 127), Houston, Texas, United States
Contact: Principal Investigator (David S Hong, MD)Utah Cancer Specialists (site 203), Salt Lake City, Utah, United States
Contact: Study coordinator (Angie Sonntag) · asonntag@utahcancer.com; studies@utahcancer.com · 801-267-5605Contact: Principal Investigator (Stephan DiSean Kendall, MD)PanOncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200), San Juan, Puerto Rico
Contact: Study coordinator (Astrid K Martínez) · astrid.martinez@panoncologytrials.com · (787) 407-3333Contact: Principal Investigator (Marcia Cruz-Correa, MD, PhD, AGAF, FASGE)
Study leads
Clinical Development
Study Chair
VM Oncology